BioCentury
ARTICLE | Finance

Ebb & Flow

August 6, 2007 7:00 AM UTC

With all the big names accounted for in the 2Q07 earnings season, the Street has rendered its verdict on the prospects going forward, punishing big pharma while giving big biotech at least the benefit of the doubt.

Indeed, the pharma space saw more than $35 billion of aggregate market cap disappear in the wake of the quarterly results posted by their top names. Biotechs, on the other hand, added about $800 million of market cap...